Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipatasertib + Atezolizumab + Docetaxel in mCRPC
NCT04404140Phase 1Terminated
- Sponsor
- Roche
- Start
- Jul 2020
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label, single-arm trial of ipatasertib in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Roche. Primary endpoints: Percentage of Participants with Adverse Events up to 35 months, Confirmed Prostate Specific Antigen Response up to 35 months and 1 more. Started Jul 2020; status: terminated.
02
Drugs
ipatasertib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04404140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04404140.